Latest Pulmonology Stories
Each of the Emerging LABA/LAMA Fixed-Dose Combinations Has Advantages Over Current Therapies on Efficacy Measures, According to Findings from Decision Resources Group BURLINGTON, Mass., April
New research report “COPD Drug Market Opportunity & Clinical Pipeline Analysis” worked out by Kuick Research is now available at MarketPublishers.com.
SAN DIEGO, April 21, 2014 /PRNewswire/ -- Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs.
OXFORD, England and PITTSBURGH, April 15, 2014 /PRNewswire/ -- Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design,
DUBLIN, Ireland, April 11, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/53hl65/global) has announced the addition of the "Global
Team PHenomenal Hope, a four-woman relay team, will cycle 3,000 miles non-stop across 12 states this June as they compete in the Race Across America. Dr.
LISBON, Portugal, April 7, 2014 /PRNewswire/ -- Hovione announced today that the United States Patent and Trademark Office (USPTO) has granted a patent
Clinical investigators at the Children’s Hospital of Eastern Ontario (CHEO) have developed a new screening tool to help diagnose obstructive sleep apnea in children.
LONDON, April 1, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
Human parainfluenza viruses, belonging to the paramyxovirus family, are a group of four distinct serotypes of enveloped single-stranded RNA viruses. They are the second most common cause of lower respiratory tract infection in younger children. Many times the host has repeat infections throughout life with symptoms that may include upper respiratory tract illness or more commonly, a cold and sore throat. It can also cause severe pneumonia in immunosuppressed people. There is currently no...